- Reducing our carbon footprint as a biotechnology company
- Quantifying CO2 emissions produced during the supply chain
- Understanding both Amicus' and our partners' GHG emissions and developing reduction targets to achieve carbon neutrality
Amicus Therapeutics
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, Amicus Therapeutics disclosed greenhouse gas emissions of 0% Scope 1 and 2 GHG emissions. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
0% Scope 1 and 2 GHG emissions
2023
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2023 | 0% Scope 1 and 2 GHG emissions |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Continued to capture risk and opportunities in our partners’ sustainability programs
- Implemented contractual obligations with suppliers to maintain good sustainability practices
- Engaged employees around good sustainability practices
- Greater efforts towards reducing our carbon footprint
🎯 Climate & Sustainability Targets
🔭 Long-term
- carbon neutrality
🌱 ESG Focus Areas
Environmental StewardshipPatientsEmployeesGovernance